Biotech News
Ascendis Pharma Reports Third Quarter 2026 Financial Results
Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ®, €59 million for SKYTROFA ®, and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of orphan medicinal product designation for
